Julian Schink,


Emeritus Chief Medical Officer, City of Hope Atlanta, Chicago and Phoenix

Julian Schink - Chief, CTCA Division of Gynecologic Oncology, Department of Surgery

Timeliness and information are key elements to a caring environment because waiting causes suffering, whether it is waiting for treatment or for information.

City of Hope Chicago
2520 Elisha Avenue
Zion, IL 60099
Gynecologic Oncology
Medical school:
The University of Texas Health Science Center at San Antonio
Obstetrics and Gynecology - Northwestern University Feinberg School of Medicine, Chicago, IL
Gynecologic Oncology - UCLA Medical Center, Los Angeles, CA

Diplomate, American Board of Obstetrics and Gynecology

Obstetrics and Gynecology & Gynecologic Oncology - American Board of Obstetrics and Gynecology

About Me

Julian Schink, MD, is Emeritus Chief Medical Officer for City of Hope® Cancer Centers Atlanta, Chicago and Phoenix. After serving for four years as chief medical officer, Dr. Schink retired in 2022. He continues to serve City of Hope in a variety of ways, including his role in a program that connects prospective patients with a physician who can provide advice and guidance as they begin their cancer treatment journey at City of Hope.

With more than 25 years of oncology experience, and board certified in gynecologic oncology, obstetrics and gynecology, Dr. Schink is dedicated to caring for patients and advancing the treatment of gynecologic malignancies. He is an expert in surgical and chemotherapy treatments for patients with gynecologic cancers, including ovarian cancer, cervical cancer, uterine cancer and gestational trophoblastic neoplasia.

“As a gynecologic oncologist, my single, most important goal is to fight cancer,” says Dr. Schink. “Ongoing advances in the treatment of gynecologic oncology are offering physicians more options and patients greater hope.”

Dr. Schink earned a medical degree from the University of Texas Health Science Center at San Antonio in San Antonio, Texas. Following medical school, he completed a four-year residency in obstetrics and gynecology at Northwestern University Medical School in Chicago. Dr. Schink also completed a fellowship in gynecologic oncology at the University of California, Los Angeles Medical School in Los Angeles, California.

He has held numerous academic positions, including vice chair of obstetrics and gynecology and professor at the University of Wisconsin Medical School; and, subsequently, an endowed professorship at Northwestern University Feinberg School of Medicine as the John and Ruth Brewer Chair in Gynecology and Cancer Research. He served as Chief Medical Officer of City of Hope’s Atlanta, Chicago and Phoenix cancer centers (previously Cancer Treatment Centers of America) for four years.

Published in numerous medical journals and more than 125 publications dedicated to oncology and women’s health, Dr. Schink has also authored more than 10 chapters in oncology textbooks, focusing much of his academic work on gestational trophoblastic disease. He served as principal investigator and co-investigator for many clinical trials responsible for improving and expanding cancer treatment options.

Licensed by the States of Illinois, California, Wisconsin and Michigan, Dr. Schink has been a member of and held leadership positions at several medical organizations. These include the American College of Obstetricians & Gynecologists, the Society of Gynecologic Oncology and the Gynecologic Cancer Foundation. Dr. Schink has also won several awards for his outstanding work, including listings on America’s Top Doctors, The Best Doctors in America and Chicago Super Doctors.

In addition to his work, Dr. Schink is passionate about sail boating, and has participated in several competitive sailing events over the years. He enjoys spending time with his wife, Sharon. Together, they have four adult children, three grandchildren and two dogs.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.